- Home
- WY vs BBIO Comparison
WY vs BBIO Comparison
Compare WY & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WY | BBIO |
|---|---|---|
| Founded | 1900 | 2015 |
| Country | United States | United States |
| Employees | 9517 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4B | 15.3B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WY | BBIO |
|---|---|---|
| Price | $25.28 | $68.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 22 |
| Target Price | $29.00 | ★ $79.91 |
| AVG Volume (30 Days) | ★ 6.8M | 2.8M |
| Earning Date | 04-30-2026 | 04-09-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | ★ 27.09 |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $6,905,000,000.00 | $221,902,000.00 |
| Revenue This Year | $5.49 | $128.68 |
| Revenue Next Year | $8.69 | $83.58 |
| P/E Ratio | $56.74 | ★ N/A |
| Revenue Growth | N/A | ★ 2285.27 |
| 52 Week Low | $21.16 | $28.33 |
| 52 Week High | $31.66 | $84.94 |
Technical Indicators
Market Signals| Indicator | WY | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 39.59 |
| Support Level | $26.37 | $72.82 |
| Resistance Level | $27.75 | $76.81 |
| Average True Range (ATR) | 0.70 | 4.39 |
| MACD | -0.23 | -0.47 |
| Stochastic Oscillator | 5.26 | 26.97 |
Price Performance
Historical ComparisonAbout WY Weyerhaeuser Company
Weyerhaeuser Co ranks among the world's key forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.